|
  |
MiddleBrook Pharmaceuticals, Inc.
(formerly known as Advancis Pharmaceutical Corp.)
Germantown, Maryland |
www.middlebrookpharma.com |
| Speciality pharma company. Pulsatile formulation of antibiotics to achieve clinical advantages of existing antibiotics. Preclinical and clinical development. |
Press releases |
| Last investment in 2003. |
|
 |
Affymax, Inc.
Palo Alto, California |
www.affymax.com |
| Clinical stage company. Hematide, a mimetic of erythropoetin, in clinical development. |
Press releases |
| Last investment in 2005. |
|
 |
Agensys, Inc.
Santa Monica, California |
www.agensys.com |
| Drug target identification, drug discovery and development for the treatment of cancer. Human monoclonal antibodies. Preclinical development. |
Press releases |
| Last investment in 2007. |
|
 |
Entelos, Inc.
Foster City, California |
www.entelos.com |
| Computer simulation of physiological processes. Metabolic and inflammatory diseases. Virtual patients. |
Press releases |
| Last investment in 2001. |
|
 |
PharmAthene, Inc.
Annapolis, Maryland |
www.pharmathene.com |
| Biopharmaceutical company with focus on biodefense. Initially, inhaled anthrax infections. Drug development. |
Press releases |
| Last investment in 2005. |
|
 |
Raven Biotechnologies, Inc.
South San Francisco, California |
www.ravenbio.com |
| Clinical stage cancer company. Monoclonal antibodies. |
Press releases |
| Last investment in 2007. |
|
 |
Tolerx, Inc.
Cambridge, Massachusetts |
www.tolerx.com |
| Clinical stage company with a significant immunology platform to treat autoimmune diseases. |
Press releases |
| Last investment in 2006. |
|
 |
AGY Therapeutics, Inc.
South San Francisco, California |
www.agyinc.com |
| Drug target identification, drug discovery and development for the treatment of neurological and psychiatric diseases of the central nervous system, such as stroke, Alzheimer's Disease, brain tumor and depression. Human monoclonal antibodies and small molecules. Preclinical development. |
Press releases |
| Exit in 2004. |
|
 |
Axxima Pharmaceuticals AG
Martinsried, Germany |
www.axxima.com |
| Host and pathogen kinase inhibitors for the treatment of infectious diseases. Preclinical development |
Press releases |
| Exit in 2004. |
|
 |
Corgentech, Inc.
South San Francisco, California |
www.corgentech.com |
| Transcription factors as targets for inhibitors to treat diseases by regulating gene expression. Prevention of bypass graft failure, rheumatoid arthritis. Small molecules. Preclinical and clinical development (Phase III). |
Press releases |
| Exit in 2005. |
|
 |
Corus Pharma, Inc.
Seattle, Washington |
www.coruspharma.com |
| Focus on respiratory diseases. Clinical trial for an inhaled antibiotic in cystic fibrosis. Clinical trials for the treatment of asthma. |
Press releases |
| Exit in 2005. |
|
 |
TeGenero Immuno Therapeutics AG
Wuerzburg, Germany |
www.tegenero.com |
| Novel immunomodulators to treat diseases related to malfunction of T-lymphocytes. Autoimmune diseases, such as rheumatoid arthritis. Humanized monoclonal antibodies. Preclinical develompent. |
Press releases |
| Exit in 2005. |
|
|
|
